• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries
ConclusionThe model results showed a strong dependence of the results on the country-specific costs for stroke treatment. The use of the investigated screening method is close to cost-neutral or cost-reducing in the Western European countries and Greece. In countries with low price levels, higher cost increases due to AF screening are to be expected. Lower costs of anticoagulation, which are expected due to the upcoming patent expiry of direct anticoagulants, have a positive effect on the cost result.
Source: Health Economics Review - February 26, 2022 Category: International Medicine & Public Health Source Type: research

The management of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: protocol for a systematic review and meta-analysis - Galvain T, Hill R, Donegan S, Lisboa P, Lip GYH, Czanner G.
BACKGROUND: Atrial fibrillation affects an estimated 33 million individuals worldwide and is a major cause of stroke, heart failure, and death. Anticoagulants substantially reduce the risk of stroke but are also associated with an increased risk of bleedin...
Source: SafetyLit - April 14, 2022 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Cost-effectiveness of targeted screening for non-valvular atrial fibrillation in the United Kingdom in older patients using digital approaches
CONCLUSIONS: Screening for NVAF at ≥75 years of age could result in fewer NVAF-related strokes. NVAF screening is cost-effective and may be cost-saving depending on the program chosen.PMID:36757910 | DOI:10.1080/13696998.2023.2179210
Source: Journal of Medical Economics - February 9, 2023 Category: Health Management Authors: Shreeya Patel Thitima Kongnakorn Andreas Nikolaou Yassir Javaid Ruth Mokgokong Source Type: research

Hospitalizations For Atrial Fibrillation Are On The Rise
In recent years there has been an explosion of interest in atrial fibrillation (AF), the most common heart rhythm disorder. Although it is sometimes thought to be relatively benign, AF increases the risk of stroke if untreated. Even if treated, it can be the source of significant discomfort and can contribute to additional complications, especially when accompanied by other cardiovascular conditions. Now a new study published in Circulation finds that hospitalizations for AF are on the increase, and this may have important implications for the delivery and economics of health care in the coming years.
Source: Forbes.com Healthcare News - May 19, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population
Conclusions The clinical benefits of appropriate anticoagulation are widely recognised; however, full implementation can be difficult and costly. Therefore, the development of models can support the planning process by facilitating discussion among stakeholders on how best they can reach full implementation. The model is flexible and can be adapted to suit different payers.
Source: Applied Health Economics and Health Policy - June 15, 2015 Category: Health Management Source Type: research

Inflammation, oxidative stress and postoperative atrial fibrillation in cardiac surgery
Publication date: Available online 24 June 2015 Source:Pharmacology & Therapeutics Author(s): M. Zakkar , R. Ascione , A.F. James , G.D. Angelini , M.S. Suleiman Postoperative atrial fibrillation (POAF) is a common complication of cardiac surgery that occurs in up to 60% of patients. POAF is associated with increased risk of cardiovascular mortality, stroke and other arrhythmias that can impact on early and long term clinical outcomes and health economics. Many factors such as disease-induced cardiac remodelling, operative trauma, changes in atrial pressure and chemical stimulation and reflex sympathetic/ parasym...
Source: Pharmacology and Therapeutics - June 26, 2015 Category: Drugs & Pharmacology Source Type: research

Clinical and Cost Effectiveness of Apixaban Compared to Aspirin in Patients with Atrial Fibrillation: An Australian Perspective
ConclusionCompared to aspirin, apixaban is likely to be cost effective in preventing thromboembolic disease among VKA unsuitable patients with atrial fibrillation.
Source: Applied Health Economics and Health Policy - October 3, 2016 Category: Health Management Source Type: research

Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in the Netherlands.
CONCLUSION: Dabigatran treatment was as a predictor for lower cardiology costs and lower total hospital care costs in AF patients that initiated oral anticoagulation. PMID: 28766370 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - August 4, 2017 Category: Health Management Tags: J Med Econ Source Type: research

Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records
This study aims to describe overall annual costs per patient for management of non-valvular AF in a primary healthcare (PHC) setting and compare these costs between the groups of patients treated with vitamin K antagonists, antiplatelets or non-treated through a population-based study conducted with electronic health records. We analysed annual costs per person of 19,787 patients in 2012; PHC visits, hospital admissions, AF-related events requiring hospital admission, referrals to secondary specialists, sick leave, diagnostic tests and laboratory tests at PHC level, including INR determinations performed in PHC, and drug t...
Source: The European Journal of Health Economics - February 20, 2018 Category: Health Management Source Type: research

Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria.
CONCLUSION: The economic burden of NVAF is important in Algeria, largely driven by untreated and INR-uncontrolled patients. There is a lack of information on the Algerian healthcare system that could increase uncertainty around this assessment, but it clearly establishes the importance of NVAF as a public health concern. PMID: 30238813 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - September 23, 2018 Category: Health Management Tags: J Med Econ Source Type: research

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
CONCLUSIONS: In patients with NVAF or VTE, rivaroxaban treatment is likely to be cost-effective and potentially cost-saving alternative to VKA in the Netherlands. PMID: 30614320 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 8, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Cost-Effectiveness of Extended and One-Time Screening Versus No Screening for Non-Valvular Atrial Fibrillation in the USA
ConclusionsOur analysis suggests that, screening the general population at age 75  years for NVAF is cost effective at a WTP threshold of $100,000. Both extended screening and one-time screening for NVAF are expected to provide health benefits at an acceptable cost.
Source: Applied Health Economics and Health Policy - December 16, 2019 Category: Health Management Source Type: research

Pages: 1  2  3  4  5